<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01194336</url>
  </required_header>
  <id_info>
    <org_study_id>WRAIR 1650</org_study_id>
    <secondary_id>A-16072</secondary_id>
    <nct_id>NCT01194336</nct_id>
  </id_info>
  <brief_title>Evaluation of Three Potential Central Nervous System (CNS) Pretreatments for Soman Exposure on Human Performance</brief_title>
  <official_title>Evaluation of Three Potential CNS Pretreatments for Soman Exposure - Huperzine A, Donepezil, and Galantamine - on Human Performance</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>U.S. Army Medical Research and Materiel Command</agency>
      <agency_class>U.S. Fed</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Walter Reed Army Institute of Research (WRAIR)</agency>
      <agency_class>U.S. Fed</agency_class>
    </collaborator>
  </sponsors>
  <source>U.S. Army Medical Research and Materiel Command</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The primary objective of this study is to determine whether huperzine A, donepezil, and
      galantamine impact militarily relevant aspects of neurocognitive performance in humans,
      compared to placebo.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      The primary objective of this study is to determine whether huperzine A, donepezil, and
      galantamine impact militarily relevant aspects of neurocognitive performance in humans,
      compared to placebo.

      Secondary: Secondary objectives are to correlate neurocognitive performance effects with
      degree of inhibition and therefore sequestration of red blood cell AChE by huperzine A,
      donepezil, and galantamine, and to monitor the safety of the study drugs in healthy adult
      (18-39 years) males and females.

      In a double-blind, randomized, placebo-controlled, parallel-groups design, normal, healthy,
      adult male and female volunteers will be administered one of the drug/doses. They will be
      tested prior to and periodically for militarily relevant performance tasks for up to 8 hours
      post-dose and for cholinesterase levels via finger prick.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>February 2012</start_date>
  <completion_date type="Actual">October 2012</completion_date>
  <primary_completion_date type="Actual">October 2012</primary_completion_date>
  <study_type>Observational</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Cohort</observational_model>
    <time_perspective>Prospective</time_perspective>
  </study_design_info>
  <primary_outcome>
    <measure>Observe military relevant neurocognitive performance in humans taking huperzine A, donepezil and galantamine compared to placebo.</measure>
    <time_frame>6pm Day 1 to 7pm Day 2</time_frame>
    <description>The primary objective of this study is to determine whether huperzine A (a nutraceutical), donepezil (Aricept®), and galantamine (Razadyne®), impact militarily relevant aspects of neurocognitive performance in humans, compared to placebo.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Correlate neurocognitive performance effects of huperzine A, donepezil and galantamine and to monitor the safety of the study drugs in healthy adults.</measure>
    <time_frame>6pm Day 1 to 7pm Day 2</time_frame>
    <description>Secondary objectives are to correlate neurocognitive performance effects with degree of sequestration of red blood cell AChE by huperzine A, donepezil, and galantamine, and to monitor the safety of the study drugs in healthy adults.</description>
  </secondary_outcome>
  <number_of_groups>7</number_of_groups>
  <enrollment type="Actual">84</enrollment>
  <condition>Biomarkers, Pharmacological</condition>
  <arm_group>
    <arm_group_label>Huperzine A: 100 ug</arm_group_label>
  </arm_group>
  <arm_group>
    <arm_group_label>Huperzine A: 200 ug</arm_group_label>
  </arm_group>
  <arm_group>
    <arm_group_label>Donepezil: 2.5 mg</arm_group_label>
  </arm_group>
  <arm_group>
    <arm_group_label>Donepezil: 5 mg</arm_group_label>
  </arm_group>
  <arm_group>
    <arm_group_label>Galantamine: 4 mg</arm_group_label>
  </arm_group>
  <arm_group>
    <arm_group_label>Galantamine: 8 mg</arm_group_label>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo</arm_group_label>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Huperzine A</intervention_name>
    <description>dosage form: tablet dose frequency: once only</description>
    <arm_group_label>Huperzine A: 100 ug</arm_group_label>
    <arm_group_label>Huperzine A: 200 ug</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Donepezil</intervention_name>
    <description>dosage form: tablet dosage frequency: once only</description>
    <arm_group_label>Donepezil: 2.5 mg</arm_group_label>
    <arm_group_label>Donepezil: 5 mg</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Galantamine</intervention_name>
    <description>dosage form: tablet dosage frequency: once only</description>
    <arm_group_label>Galantamine: 4 mg</arm_group_label>
    <arm_group_label>Galantamine: 8 mg</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <description>dosage form: tablet dosage frequency: once only</description>
    <arm_group_label>Placebo</arm_group_label>
  </intervention>
  <eligibility>
    <study_pop>
      <textblock>
        Healthy adults (18-39 years) males and females, military or civilian
      </textblock>
    </study_pop>
    <sampling_method>Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  All healthy men and women 18 to 39 years of age are eligible to participate.

        Exclusion Criteria:

        Must be able to swallow whole pills.

          -  Self-reported habitual nightly sleep amounts outside the target range of 6-8 hours
             (i.e., less than 6 hours per night or more than 8 hours per night, on average)

          -  Cardiovascular disease (to include but not limited to arrhythmias, valvular heart
             disease, congestive heart failure, family history of sudden cardiac death or
             myocardial infarction) as determined by participant self report.

          -  Current hypertension or high blood pressure (greater than 140/90)

          -  Neurologic disorder (to include but not limited to epilepsy or another seizure
             disorder, amnesia for any reason, hydrocephalus, MS, narcolepsy or other sleep
             disorders)

          -  Kidney disease

          -  History of psychiatric disorder requiring hospitalization or psychiatric medication
             for any length of time

          -  Beck Depression Inventory score of 14 or above

          -  Underlying pulmonary disease requiring daily inhaler use

          -  Regular nicotine use (or addiction) (defined as more than 1 cigarette or equivalent
             per week) within the last 3 years

          -  Heavy alcohol use (more than 2 drinks per day; http://www.cdc.gov/alcohol/faqs.htm#10)

          -  Use of other illicit drugs (to include but not limited to benzodiazepines,
             amphetamines, cocaine, marijuana)

          -  Known liver disease or liver abnormalities as determined by a laboratory test

          -  Known ulcer disease or risk of ulcer disease (stomach bleeding)

          -  Self-reported history of caffeine use in excess of 400 mg (8 caffeinated sodas or 3-4
             cups, each ~ 6 oz, of coffee) per day on average

          -  Pregnancy (females)

          -  Breast-feeding (females)

          -  Prior anaphylactic reaction, angioedema, or other severe psychological reactions to
             any of the test compounds
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>39 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>MAJ James E Moon, MC</last_name>
    <role>Principal Investigator</role>
    <affiliation>Walter Reed Army Institute of Research (WRAIR)</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Walter Reed Army Institute of Research</name>
      <address>
        <city>Silver Spring</city>
        <state>Maryland</state>
        <zip>20910</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>May 2017</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>August 31, 2010</study_first_submitted>
  <study_first_submitted_qc>September 2, 2010</study_first_submitted_qc>
  <study_first_posted type="Estimate">September 3, 2010</study_first_posted>
  <last_update_submitted>May 2, 2017</last_update_submitted>
  <last_update_submitted_qc>May 2, 2017</last_update_submitted_qc>
  <last_update_posted type="Actual">May 3, 2017</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Central nervous system</keyword>
  <keyword>Cholinesterase</keyword>
  <keyword>Neurocognitive performance testing</keyword>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Donepezil</mesh_term>
    <mesh_term>Galantamine</mesh_term>
    <mesh_term>Huperzine A</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

